Literature DB >> 18319361

A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system.

Hans J Roethig1, Shixia Feng, Qiwei Liang, Jianmin Liu, William A Rees, Barbara K Zedler.   

Abstract

This randomized, controlled, forced-switching, open-label, parallel-group study in 97 adult male and female smokers of conventional cigarettes evaluated biomarkers of tobacco smoke exposure and cardiovascular risk factors. After baseline measurements, smokers were either switched to a second-generation electrically heated cigarette smoking system (EHCSS) or continued smoking conventional cigarettes for 12 months. Biomarkers of exposure and cardiovascular risk factors were measured at 0.5, 1, 2, 3, 4, 5, 6, 9, and 12 months. There was a rapid and sustained reduction in all biomarkers of exposure after switching to the EHCSS, with statistically significant reductions from baseline in nicotine equivalents (-18%), plasma cotinine (-16%), total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (-73%), total 1-hydroxypyrene (-53%), urine mutagenicity (-52%), 4-aminobiphenyl hemoglobin adducts (-43%), carboxyhemoglobin AUC7-23 h (-80%), and 3-hydroxypropylmercapturic acid (-35%). These reductions in exposure in the EHCSS group were associated with statistically significant and pathophysiologically favorable changes in several cardiovascular risk factors, including white blood cell count (-0.78 x 10(3)/microL), hemoglobin (-0.16 g/dL), hematocrit (-0.44%), urine 11-dehydrothromboxane B2 (-374 ng/24 h), and high-density lipoprotein cholesterol (+5 mg/dL).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319361     DOI: 10.1177/0091270008315316

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

Review 1.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 2.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

3.  Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers.

Authors:  Steven G Carmella; Menglan Chen; Shaomei Han; Anna Briggs; Joni Jensen; Dorothy K Hatsukami; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2009-04       Impact factor: 3.739

4.  High throughput liquid chromatography-tandem mass spectrometry assay for mercapturic acids of acrolein and crotonaldehyde in cigarette smokers' urine.

Authors:  Steven G Carmella; Menglan Chen; Adam Zarth; Stephen S Hecht
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-07-15       Impact factor: 3.205

5.  The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US.

Authors:  Mitchell Zeller; Dorothy Hatsukami
Journal:  Tob Control       Date:  2009-02-24       Impact factor: 7.552

6.  Systemic inflammation in 222.841 healthy employed smokers and nonsmokers: white blood cell count and relationship to spirometry.

Authors:  José Antonio Fiz Fernández; Josép Morera Prats; José Vicente Monsonis Artero; Alberto Calvo Mora; Anna Vazquez Fariñas; Anna Espinal; José Antonio Gelpi Méndez
Journal:  Tob Induc Dis       Date:  2012-05-21       Impact factor: 2.600

Review 7.  Interventions to reduce harm from continued tobacco use.

Authors:  Nicola Lindson-Hawley; Jamie Hartmann-Boyce; Thomas R Fanshawe; Rachna Begh; Amanda Farley; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2016-10-13

8.  Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect.

Authors:  Brian K Nordskog; Buddy G Brown; Kristin M Marano; Leanne R Campell; Bobbette A Jones; Michael F Borgerding
Journal:  Inhal Toxicol       Date:  2015-03-19       Impact factor: 2.724

9.  Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach.

Authors:  Evan O Gregg; Emmanuel Minet; Michael McEwan
Journal:  Biomarkers       Date:  2013-07-31       Impact factor: 2.658

10.  Menthol's potential effects on nicotine dependence: a tobacco industry perspective.

Authors:  Valerie B Yerger
Journal:  Tob Control       Date:  2011-05       Impact factor: 6.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.